X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs LUPIN LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA LUPIN LTD ASTRAZENECA PHARMA/
LUPIN LTD
 
P/E (TTM) x 104.7 20.1 520.4% View Chart
P/BV x 14.9 2.7 547.0% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ASTRAZENECA PHARMA   LUPIN LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
LUPIN LTD
Mar-17
ASTRAZENECA PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,2851,750 73.4%   
Low Rs6341,384 45.8%   
Sales per share (Unadj.) Rs189.6387.4 48.9%  
Earnings per share (Unadj.) Rs-0.256.6 -0.4%  
Cash flow per share (Unadj.) Rs3.876.8 5.0%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs68.6298.9 23.0%  
Shares outstanding (eoy) m25.00451.58 5.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x5.14.0 125.1%   
Avg P/E ratio x-4,712.727.7 -17,035.0%  
P/CF ratio (eoy) x249.620.4 1,224.0%  
Price / Book Value ratio x14.05.2 266.7%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m23,988707,513 3.4%   
No. of employees `0001.616.8 9.3%   
Total wages/salary Rs m1,60528,495 5.6%   
Avg. sales/employee Rs Th3,040.210,418.3 29.2%   
Avg. wages/employee Rs Th1,029.21,697.0 60.7%   
Avg. net profit/employee Rs Th-3.31,523.0 -0.2%   
INCOME DATA
Net Sales Rs m4,740174,943 2.7%  
Other income Rs m921,065 8.6%   
Total revenues Rs m4,832176,008 2.7%   
Gross profit Rs m-13044,931 -0.3%  
Depreciation Rs m1019,122 1.1%   
Interest Rs m01,525 0.0%   
Profit before tax Rs m-13935,349 -0.4%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m59,785 0.1%   
Profit after tax Rs m-525,575 -0.0%  
Gross profit margin %-2.725.7 -10.7%  
Effective tax rate %-3.727.7 -13.2%   
Net profit margin %-0.114.6 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,726119,542 2.3%   
Current liabilities Rs m2,43561,206 4.0%   
Net working cap to sales %6.133.3 18.4%  
Current ratio x1.12.0 57.3%  
Inventory Days Days7476 97.0%  
Debtors Days Days4190 45.4%  
Net fixed assets Rs m1,035131,660 0.8%   
Share capital Rs m50903 5.5%   
"Free" reserves Rs m942134,073 0.7%   
Net worth Rs m1,716134,976 1.3%   
Long term debt Rs m056,478 0.0%   
Total assets Rs m4,156266,073 1.6%  
Interest coverage xNM24.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.7 173.5%   
Return on assets %-0.110.2 -1.2%  
Return on equity %-0.318.9 -1.6%  
Return on capital %019.3 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37581,885 0.5%   
Fx outflow Rs m47021,506 2.2%   
Net fx Rs m-9660,378 -0.2%   
CASH FLOW
From Operations Rs m-841,148 -0.0%  
From Investments Rs m-146-25,287 0.6%  
From Financial Activity Rs m8624,332 19.9%  
Net Cashflow Rs m70920,193 3.5%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 15.7 31.9 49.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   12,856 98,259 13.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS